Eli Lilly reports Omvoh data: Eli Lilly stock trades 1.46 percent lower
Published on 10/16/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLilly pipeline and earnings calendar
- Omvoh reached 27.70 percent comprehensive disease control in ulcerative colitis on October 15, 2026.
- Consensus diluted earnings per share for October 29, 2026, stands at USD 7.54 versus USD 7.02.
- Eli Lilly stock trades at EUR 1,116.80 at 9:14 a.m. CEST at Lang & Schwarz on October 16, 2026, 1.46 percent below the Xetra close of October 15, 2026.
Eli Lilly reports new Omvoh data as Eli Lilly stock trades at EUR 1,116.80, down 1.46 percent versus the Xetra close of October 15, 2026. In a release dated October 15, 2026, Eli Lilly and Company said Omvoh achieved comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year.
Omvoh delivers two trial figures
The clinical update supplied a clear comparison. In LUCENT-2, 27.70 percent of Omvoh-treated ulcerative colitis patients achieved comprehensive disease control, versus 14.00 percent receiving placebo. In VIVID-1, 20.40 percent of patients with Crohn's disease achieved corticosteroid-free deep remission, compared with 2.00 percent on placebo, according to Eli Lilly and Company.
Three dated Lilly milestones
The recent sequence began on August 5, 2026, when Eli Lilly reported quarterly revenue of USD 22.97 billion and diluted earnings per share of USD 8.38, compared with USD 6.40 expected, according to MarketBeat. On September 30, 2026, the company said its investigational EloraTZP combination produced weight loss of up to 23.30 percent over 48 weeks in a Phase 2b trial, as reported by Yahoo Finance.
The current event came on October 15, 2026, with the Omvoh results and an update on the company's upcoming report. The two clinical figures give investors a measurable readout on Lilly's immunology pipeline before the next financial checkpoint.
What comes next for Lilly earnings?
Eli Lilly will announce third-quarter 2026 results on October 29, 2026, with its conference call scheduled for 10:00 a.m. Eastern time, according to the company's official release. Wall Street expects diluted earnings per share of USD 7.54, up from USD 7.02 in the comparable quarter, a 7.40 percent increase, according to Yahoo Finance. Lilly's next listed investor event is Innovation Day on December 7, 2026, according to the company's investor calendar.
Stock trades below Xetra close
Eli Lilly and Co. stock was trading intraday at EUR 1,116.80 at Lang & Schwarz on October 16, 2026, at 9:14 a.m. CEST, down 1.46 percent versus the Xetra close of October 15, 2026 at EUR 1,133.40. The stock remains below its 52-week high of EUR 1,137.80, while its 52-week low is EUR 662.90.
The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.
Eli Lilly and Co. facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 16, 2026, 9:14 a.m. CEST): EUR 1,116.80
- Change versus Xetra close: minus 1.46 percent
- Xetra close (October 15, 2026): EUR 1,133.40
- Market capitalization: EUR 1,052.2 billion (as of October 16, 2026)
- 52-week range: EUR 662.90-1,137.80 (as of October 16, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
